First-line use of enfuvirtide-containing HAART regimen with dramatic clinical and immunological improvement in three cases [4]

AIDS

Volumn 20, Issue 3, 2006, Pages 471-473

  Bourgarit, Anne ^a   Lascoux, Caroline ^a   Palmer, Pierre ^a   Tuleja, Ewa ^a   Pintado, Claire ^a   Farge, Dominique ^a   Sereni, Daniel ^a  

^a SAINT LOUIS HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; ENFUVIRTIDE; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; TUBERCULOSTATIC AGENT; ZIDOVUDINE;

ABDOMINAL INFECTION; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ASPIRATION PNEUMONIA; BRAIN ATROPHY; CASE REPORT; CAUSE OF DEATH; CD4 LYMPHOCYTE COUNT; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG INDICATION; DRUG SUBSTITUTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITAL ADMISSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYDROCEPHALUS; KIDNEY FAILURE; LABORATORY TEST; LETTER; MALE; NEUROIMAGING; NEUTROPENIA; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TREATMENT OUTCOME; TUBERCULOSIS;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 33645034361     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000199826.72359.9d     Document Type: Letter

References (2)

1. Lazzarin A, Clotet B, Cooper D, Reynes J, Arasteh K, Nelson M, et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med 2003; 348:2186-2195.
2. Barretina J, Blanco J, Bonjoch A, Llano A, Clotet B, Este JA. Immunological and virological study of enfuvirtide-treated HIV-positive patients. AIDS 2004; 18:1673-1682.